Future exploration of tumor immunobiology and advances in mAb (glyco)engineering will certainly produce novel ICIs that hit other immune checkpoints, such as lymphocyte activation gene 3 (LAG-3 or CD223), expressed on T-cells, Treg, B-cells, NK, and myeloid cells. This evidence concerns the gene LAG3 and neoplasm.